Building a future-proof regulatory system
Simpler, faster, better – let’s not miss the opportunity to revamp the EU pharmaceutical regulatory framework to transform lives.
innovative medicines
Only bold reform will expand access to innovative medicines in the UK
Greater collaboration between industry, government, policymakers and the NHS will be critical for treatment options in the UK to match the pace of scientific innovation. What is our route to achieving timely patient access across the country like our European neighbours?
The call for an EU Action Plan for rare diseases
Driving excellence: A new EU Action Plan for rare diseases that drives innovation, creativity and competitiveness can position the EU as a leader on the global stage.
EU HTA: If we want faster access to cancer treatment for all Europeans, we need to get it right
In January 2025 the EU HTA Regulation will become reality. Let’s work together to ensure it facilitates faster patient access to new cancer treatments.
Dutch drugs association wants clear, predictable reimbursement procedures from pharma package [Advocacy Lab Content]
The Dutch innovative medicines association, VIG, says amendments to the pharmaceutical legislation adopted by the European Parliament aren’t enough to ease concerns.